Background: We conducted a phase II study of oral capecitabine rapidly disintegrating tablets given concurrently with radiation therapy (RT) to assess progression-free survival (PFS) in children with newly diagnosed diffuse intrinsic pontine gliomas (DIPG).
INTRODUCTION
While the overall survival (OS) for children with brain tumors has improved substantially over the last 30 years, the outcome for children with diffuse intrinsic pontine gliomas (DIPG) remains dismal.
The diagnosis of DIPG is based on characteristic magnetic resonance imaging (MRI) findings and a clinical history of cranial nerve deficits and long-tract signs. 1 Focal radiation therapy (RT) often provides symptomatic improvement and prolongs progression-free survival (PFS) and OS; however, the 2-year OS remains less than 10%. 2, 3 Because DIPG remains a radiographic diagnosis, biologic data to guide therapeutic choices are limited and have largely been extrapolated from data in adults and children with nonbrainstem high-grade gliomas.
Unfortunately, numerous clinical trials that have coupled chemotherapy or biologic therapy with RT have failed to significantly impact survival in children with DIPG. 2, [4] [5] [6] [7] [8] [9] [10] [11] [12] Capecitabine is an oral fluoropyrimidine carbamate prodrug that exploits high intratumoral concentrations of thymidine phosphorylase (TP) to preferentially generate high concentrations of 5-fluorouracil (5-FU) in tumor tissue. Capecitabine is rapidly absorbed after oral administration, and then metabolized through a three-step enzymatic process with the final stage of this conversion mediated by TP. 13 Many tumor cells, including gliomas, have been shown to express high levels of TP. Radiation also induces TP, with studies in U87 glioblastoma xenografts demonstrating a 70-fold increase in TP expression following a single dose of radiation. 14 Thus, the combination of radiation and capecitabine is hypothesized to result in higher concentrations of 5-FU in tumor cells with capecitabine alone. Furthermore, 5-FU and capecitabine are radiation sensitizers and may enhance the therapeutic effect of RT. 15, 16 Capecitabine plus concomitant radiotherapy has been well tolerated in both adults and children with newly diagnosed gliomas. 17 A prior Pediatric Brain Tumor Consortium (PBTC) trial demonstrated that the recommended phase II capecitabine dose during radiotherapy for children with newly diagnosed high-grade or brainstem gliomas was 650 mg/m 2 /dose administered twice daily. 18 Single-agent capecitabine, 1,250 mg/m 2 /dose, administered twice daily for 14 consecutive days of a 21-day course, was administered after radiotherapy for three courses. Of note, a new rapidly disintegrating tablet (RDT) formulation was created for the phase I and II trials to facilitate enrollment of children unable to swallow pills. Preliminary pharmacokinetic (PK) data from the phase I trial demonstrated that the disposition of the RDT in children was similar to that of adults receiving the standard capecitabine formulation. 18 The primary objective of this study was to estimate the PFS distribution for children with newly diagnosed DIPG treated with the combination of capecitabine and RT and compare to a contemporary historical control. Secondary objectives were to (1) estimate the OS, (2) further characterize the safety profile of capecitabine plus concomitant radiotherapy, (3) further characterize the PKs of capecitabine RDTs, and (iv) describe radiographic changes including diffusion tensor imaging (DTI) variables in response to therapy. Since DIPG is a rare disease, this trial and the preceding phase I trial were prospectively designed to have the same inclusion/exclusion criteria so that evaluable patients treated at the maximum tolerated dose (MTD) in the phase I trial could also be included in the phase II analyses.
METHODS

Eligibility
Children 3-17 years of age with newly diagnosed DIPG were eligible. Histologic diagnosis was not required. No prior therapy other than surgery or corticosteroid therapy was allowed. Patients were also required to have a Karnofsky (patients >16 years) or Lansky (patients ≤16 years) performance status of ≥50; adequate hematologic function (absolute neutrophil count ≥1,000/mm 3 , platelets ≥100,000/mm 3 , hemoglobin ≥8 g/dl); age appropriate renal function; and adequate hepatic function (bilirubin ≤1.5× and SGPT ≤5× the institutional upper limit of normal for age). Patients were excluded if they were receiving other anticancer or experimental therapy; had uncontrolled infection or significant systemic disease; had a known hypersensitivity to capecitabine components; were receiving warfarin, sorivudine, or related analogues; or were pregnant or lactating. If applicable, patients were required to agree to use medically acceptable forms of birth control. The institutional review boards of each PBTC institution approved the protocol prior to patient enrollment and continuing approval was maintained throughout the study. Patients or their legal guardians signed written informed consent and assent was obtained as appropriate at the time of enrollment.
Treatment plan
This study was designed with an identical treatment plan as in the preceding phase I study. In both trials, the dose and schedule of capecitabine were different during the radiation and postradiation phases, with the goal to maximize capecitabine exposure during and for a period following radiation based on preclinical data that demonstrated a selective increase in intratumoral TP following radiation.
Additionally, capecitabine is known to be a radiosensitizing agent. 15 
Monitoring
Baseline clinical assessment for all patients included a history, physical examination, and laboratory studies, including a pregnancy test for females of childbearing potential. Testing for dihydropyrimidine dehydrogenase deficiency was not required, but recommended if a patient developed significant toxicity during therapy. During therapy, clinical assessments, including history, physical examination, and laboratory studies, were completed approximately every 3 weeks with complete blood counts performed weekly. Neuroimaging (MRI including T1, T2, FLAIR, and gradient sequences 19 ) was performed at diagnosis, week 11, end of therapy (week 20), and then every 3 months until disease progression. Diffusion imaging was performed pretreatment and at week 11. Patients were followed after the end of therapy for resolution of any treatment-related adverse events and then for progression and survival for up to 3 years.
Trial design
The Phase II design required 44 evaluable patients to detect with 90%
power and 10% type-1 error rate an absolute improvement of 15% in the 1-year PFS distribution as compared to the PBTC DIPG historical control cohort (1-year PFS of 15.9% in the historical cohort versus 30.9% hypothesized for this study). The primary efficacy endpoint was PFS, defined as the time from initiation of treatment to the earliest date of failure (disease progression or death from any cause). Progression was determined at the local institution and defined as worsening An interim analysis for futility was conducted after the 21st failure on study and the threshold for stopping the trial was not reached. Toxicity data are reported descriptively. Cox proportional hazards models were used to investigate the association of predefined neuroimaging variables of interest with PFS and OS. 19 
Pharmacokinetics
Patients consenting to participate in the PK substudy were assigned to one of three sampling schedules to maximize the information obtained from limited sampling. Initial patients were assigned to schedules A and B, which were utilized in the phase I study. 18 Subsequently, the sampling was further reduced to encourage participation and in sched- In addition to the noncompartmental approach, a population analysis was performed to describe the PK time course profile as well as to obtain PK parameter estimates in children from the pooled PK data.
A multiresponse population PK model, previously developed in adults for the main capecitabine metabolites (5 ′ -DFUR, 5-FU, and FBAL), was used to compare the adult exposure with the exposures from the pediatric studies. 20 This model was used with a Bayesian feedback analysis using NONMEM. Pediatric PK parameters and exposure estimates were subsequently compared with the expected exposure in an adult population at the same dose level.
STUDY RESULTS
Thirty-five children with DIPG, all eligible, were enrolled from February 2010 to May 2011. Thirty-four patients received at least one dose of capecitabine, and thus were evaluable for the survival and toxicity endpoints. Ten patients treated at the MTD of capecitabine on the phase I study also met the eligibility criteria for this study, bringing the total sample size to 44 evaluable patients. Patient characteristics are presented in Table 1 .
Twenty-five patients completed the entire planned protocol therapy. In five patients, treatment was stopped prior to completion due to adverse events and three withdrew from treatment; two early in course 1 due to difficulty in taking study medication, and one after the first post-RT course in the context of wound dehiscence and neutropenia. Eleven patients developed clinical (n = 3) or radiographic (n = 8, four local and four distant) progression during therapy. These results are summarized in Supplementary Table S1 .
Adverse events
The study therapy was well tolerated in the majority of patients. The most commonly reported toxicities on treatment were grade 2 or lower and expected, including palmar plantar erythrodyesthesia (hand-foot syndrome), increase in ALT, cytopenias, and vomiting.
Grade 2 and higher treatment related toxicities are presented in Table 2 . CNS necrosis grades 2-3 was reported as an adverse event in four patients after RT with capecitabine. Two patients were taken off treatment early due to this toxicity and associated symptoms.
Outcome
Figures 1 and 2 demonstrate the PFS and OS, respectively, for patients on study compared to those in the PBTC historical cohort (n = 140).
Findings were significant for earlier progression (P = 0.007) with the TA B L E 2 Capecitabine-related toxicities during treatment (n = 44) 
Neuroimaging
Forty-four evaluable patients had a total of 173 neuroimaging assessments. Forty-three patients had standard diffusion imaging with 16 at baseline (data not shown). The specific regional diffusion tensor metrics assessed were not associated with PFS due to small sample size; however, patients with higher 2D mean apparent diffusion coefficient had a relatively shorter PFS. Although the presence of necrosis or cystic enhancement after radiation based on imaging assessment at day 70 was similar in patients on this study compared to the historical control (27% vs. 21%, P = 0.42), there was a suggestion that the median volume of necrosis was increased (2.6 vs. 0.8, P = 0.07).
Pharmacokinetics
Plasma concentrations for capecitabine and the metabolites (5 ′ -DFCR, Table 3 . A large intersubject variability was observed for the PK parameters and due to the limited number of samples collected, individual observed PK parameters could not be calculated for all patients and should be interpreted with caution.
A total of 10 patients from the phase I and 15 patients from the phase II trial were included in the Bayesian feedback analysis, for a total of 561 observations. Comparison of C max and AUC of parent drug and its metabolites revealed that the pediatric PK parameters appear to be comparable to the adult data, with a slightly lower than expected exposure compared to an adult population treated at 650 mg/m 2 . 20,21
DISCUSSION
Our study sought to enhance the efficacy of RT in children with DIPG through combination therapy with capecitabine via two hypothe- RT. This is within the expected frequency for children with newly diagnosed DIPG receiving RT based on prior publications. 22 However, the volume of necrosis was noted to be higher in this study compared to the historical control and two patients discontinued therapy due to symptomatic necrosis. It is unclear if this finding contributed to the shorter PFS seen in this study.
Unfortunately, similar to previous trials in children with DIPG, the combination therapy failed to improve the outcome compared with the aggregate data from prior PBTC studies. It is unclear whether the shorter PFS in this study in the context of unchanged OS is related to larger baseline tumor volume, suggests increased pseudoprogression in response to therapy, clinical symptoms related to the increased volume of necrosis or cystic enhancement, or represents differences in treatment following progression. a Median (min-max).
TA B L E 3
As noted in prior PBTC studies, patients with tumor enhancement at baseline and over time had shorter survival. 19 In addition, as noted in In conclusion, similar to prior studies, the combination of capecitabine and RT failed to improve survival for children with DIPG. However, our knowledge about potential therapeutic targets for DIPG, and other CNS tumors, is rapidly evolving. [23] [24] [25] As such, there may be trials in which a tumor biopsy is an integral component of trial eligibility to assess the presence or absence of the putative target.
Such an approach may lead to a more accurate understanding of the trial results; however, sampling differences with a small biopsy due to tumor heterogeneity as well as delivery of the targeted therapy to the tumor at adequate exposures will continue to be major challenges in the development of effective therapies for this challenging tumor.
